Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
80%(4 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_4
3
43%
Ph not_applicable
2
29%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (14.3%)
Phase 31 (14.3%)
Phase 43 (42.9%)
N/A2 (28.6%)

Trials by Status

active_not_recruiting114%
completed571%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_2

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
completedphase_3

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

NCT04327843
completedphase_4

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

NCT01174290
completedphase_4

A Comparison of Long-acting Injectable Medications for Schizophrenia

NCT01136772
completednot_applicable

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01949662Phase 2

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Active Not Recruiting
NCT04327843Phase 3

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Completed
NCT01174290Phase 4

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Completed
NCT01136772Phase 4

A Comparison of Long-acting Injectable Medications for Schizophrenia

Completed
NCT01152697Not Applicable

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Completed
NCT00947375Phase 4

Lamictal TM, Haloperidol Decanoate in Schizophrenia

Terminated
NCT00018642Not Applicable

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7